公开(公告)号：US11956362B2

公开(公告)日：2024-04-09

申请号：US17586644

申请日：2022-01-27

Applicant: Janssen Biotech, Inc.

Inventor： Khurram Mahmood ,  Eric Matthew Bell ,  Stuart Maxwell Altman ,  Jeremy Alan Dunn ,  Sambasiva R. Pedapalli ,  Christopher Prado Dunn ,  Nerses Ohanyan ,  Anand Kothari ,  Ryan Jeffrey Southwick ,  Richard Brewster Wickersham, III

IPC: H04L29/06 ,  G16H20/00 ,  H04L9/06 ,  H04L9/32 ,  H04L9/40 ,  H04L9/00

CPC classification number: H04L9/3213 ,  G16H20/00 ,  H04L9/0637 ,  H04L63/102 ,  H04L9/50

Abstract: The subject disclosure relates to systems, devices, and methods for executing operations related to procurement of individualized medicine therapies. Also disclosed are embodiments systems, methods, and devices for accessing a wide range of individualized medicine platform modules. Furthermore, disclosed herein are individualized medicine platform systems, methods and devices communicatively coupled to blockchain computing systems comprising several nodes. The disclosed systems, methods, and devices also generate chain of custody and chain of identity event data.

公开(公告)号：US20240101697A1

公开(公告)日：2024-03-28

申请号：US18208361

申请日：2023-06-12

Applicant: Janssen Biotech, Inc. ,  Stichting VUmc

Inventor： Homer Adams ,  Francois Gaudet ,  Niels Van de Donk ,  Kris Frerichs ,  Christie Verkleij

IPC: C07K16/28 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K16/30 ,  C07K16/46

CPC classification number: C07K16/2896 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K16/2809 ,  C07K16/2878 ,  C07K16/30 ,  C07K16/468 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31

Abstract: Disclosed are methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics.

公开(公告)号：US20240067754A1

公开(公告)日：2024-02-29

申请号：US18461191

申请日：2023-09-05

Applicant: Janssen Biotech, Inc.

Inventor： Jinquan LUO ,  Lauren BOUCHER ,  Michael FELDKAMP ,  Michael DIEM ,  Anthony A. ARMSTRONG ,  Alexey TEPLYAKOV ,  Chichi HUANG

IPC: C07K16/42 ,  C07K14/705 ,  C07K16/00

CPC classification number: C07K16/4283 ,  C07K14/705 ,  C07K16/00 ,  C07K2317/31 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/94

Abstract: Disclosed are materials and methods for improved single chain variable fragments.

公开(公告)号：US20240067736A1

公开(公告)日：2024-02-29

申请号：US18143749

申请日：2023-05-05

Applicant: Janssen Biotech, Inc.

Inventor： Sheri Moores

IPC: C07K16/28 ,  A61K45/06 ,  A61P35/00 ,  C07K16/30

CPC classification number: C07K16/2863 ,  A61K45/06 ,  A61P35/00 ,  C07K16/303 ,  A61K2039/545

Abstract: The present disclosure provides methods of treating liver cancer in a subject in need thereof by administering a therapeutically effective amount of a bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody.

公开(公告)号：US11884722B2

公开(公告)日：2024-01-30

申请号：US18157800

申请日：2023-01-20

Applicant: Janssen Biotech, Inc.

Inventor： Ricardo Attar ,  Francois Gaudet ,  Mark Tornetta ,  Alexey Teplyakov ,  Mark Mendonca ,  Suzanne Edavettal ,  Kodandaram Pillarisetti ,  Nathan Majewski ,  Yingzhe Li ,  Leopoldo L. Luistro, III ,  Diana Chin

IPC: A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K39/0011 ,  C07K16/2809 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.

公开(公告)号：US11866499B2

公开(公告)日：2024-01-09

申请号：US16417889

申请日：2019-05-21

Applicant: Janssen Biotech, Inc.

Inventor： Philip Cooper ,  Robin Ernst ,  Rajkumar Ganesan ,  Colleen Kane ,  Michael Russell ,  Sanjaya Singh ,  Sathyadevi Venkataramani ,  Sheng-Jiun Wu

IPC: C07K16/28 ,  A61P35/00 ,  A61K45/06

CPC classification number: C07K16/2809 ,  A61P35/00 ,  A61K45/06

Abstract: The disclosure provided herein relates to monospecific and multispecific anti-TMEFF2 antibodies, and methods of producing and using the described antibodies.

公开(公告)号：US20240002494A1

公开(公告)日：2024-01-04

申请号：US18210885

申请日：2023-06-16

Applicant: Janssen Biotech, Inc.

Inventor： Jewel Johanns ,  Katherine Li ,  Colleen Marano ,  Richard Strauss ,  Hongyan Zhang ,  Christopher O'Brien ,  Omoniyi Adedokun ,  Kimberly Shields-Tuttle

IPC: C07K16/24 ,  A61P1/04

CPC classification number: C07K16/244 ,  A61P1/04 ,  A61K2039/545

Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.

公开(公告)号：US20230365684A1

公开(公告)日：2023-11-16

申请号：US18307127

申请日：2023-04-26

Applicant: Janssen Biotech, Inc.

Inventor： Patrick John Doonan ,  Rajkumar Ganesan ,  Mehabaw Getahun Derebe ,  Sathyadevi Venkataramani ,  Sanjaya Singh ,  Iqbal S. Grewal ,  Karla R. Wiehagen

IPC: C07K16/28 ,  A61K39/00 ,  A61K51/10 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61K39/4631 ,  A61K39/464411 ,  A61K39/4611 ,  C07K16/2809 ,  A61K51/1096 ,  A61K51/1027 ,  A61P35/00 ,  C07K2317/622 ,  C07K2317/22 ,  C07K2317/92 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/73 ,  C07K2317/77

Abstract: The invention provides antigen binding domains that bind myeloid cell surface antigen CD33 protein comprising the antigen binding domains that bind CD33, polynucleotides encoding them, vectors, host cells, methods of making and using them.

公开(公告)号：US20230312703A1

公开(公告)日：2023-10-05

申请号：US18128310

申请日：2023-03-30

Applicant: Janssen Biotech, Inc.

Inventor： Daphne Chan ,  Olivia Choi ,  Long-Long Gao ,  Jenny Jeyarajah ,  Shu Li ,  Katelyn Rowland ,  Vikash Sinha ,  Yanli Wang

IPC: C07K16/24 ,  A61K45/06 ,  A61P17/06 ,  A61K9/00

CPC classification number: C07K16/244 ,  A61K45/06 ,  A61P17/06 ,  A61K9/0019 ,  A61K2039/505

Abstract: A method of treating mild to moderate psoriasis in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial dose and subsequent doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.

公开(公告)号：US20230295333A1

公开(公告)日：2023-09-21

申请号：US18300683

申请日：2023-04-14

Applicant: Janssen Biotech, Inc.

Inventor： Rajesh Bandekar ,  Pamela Clemens ,  Christoph Heuck ,  Ming Qi ,  Zhilong Yuan

IPC: C07K16/28 ,  A61K38/47 ,  A61K31/454 ,  A61K31/573 ,  A61K47/26 ,  A61K47/22 ,  A61P35/00 ,  A61K47/18

CPC classification number: C07K16/2896 ,  A61K38/47 ,  A61K31/454 ,  A61K31/573 ,  A61K47/26 ,  A61K47/22 ,  A61P35/00 ,  A61K47/183 ,  A61K2039/542

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with pomalidomide and dexamethasone.